Mesna
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MESNA |
|---|---|
| Type | Drug |
| Aliases | Mesnex |
| Status | reviewed 2026-05-07 |
| Diseases | DIS-SOFT-TISSUE-SARCOMA |
| Sources | SRC-ESMO-SARCOMA-2024 SRC-NCCN-STS-2025 |
Drug Facts
| Class | Uroprotective thiol cytoprotectant |
|---|---|
| Mechanism | Thiol compound that binds and detoxifies urotoxic ifosfamide metabolites in urine, reducing the risk of hemorrhagic cystitis. It is supportive care, not an antineoplastic treatment-selection signal. |
| Typical dosing | With ifosfamide: commonly administered as a total daily mesna dose proportional to the ifosfamide dose, using IV and/or oral divided dosing according to institutional protocol. Maintain hydration and urine monitoring. |
| Ukraine registered | False |
| NSZU reimbursed | False |
Notes
Thin support-drug entity added to resolve ifosfamide-containing regimen component references. Regimen-specific mesna schedules remain authored on the regimen.
Used By
Regimens
REG-DOXORUBICIN-IFOSFAMIDE-STS- Doxorubicin + ifosfamide (soft tissue sarcoma, AI regimen)